Vanguard Group
VTVT icon

Vanguard Group’s vTv Therapeutics VTVT Stock Holding History

Vanguard Group’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.34M Buy
83,400
+36,410
+77% +$1.01M ﹤0.01% 3405
2025
Q3 		$1.09M Buy
46,990
+3,815
+9% +$66.9K ﹤0.01% 3763
2025
Q2 		$636K Buy
43,175
+1,617
+4% +$29.6K ﹤0.01% 3868
2025
Q1 		$720K Hold
41,558
– – ﹤0.01% 3798
2024
Q4 		$566K Hold
41,558
– – ﹤0.01% 3917
2024
Q3 		$560K Buy
41,558
+17,000
+69% +$282K ﹤0.01% 3942
2024
Q2 		$434K Hold
24,558
– – ﹤0.01% 4044
2024
Q1 		$578K Buy
24,558
+1,039
+4% +$13.2K ﹤0.01% 3979
2023
Q4 		$270K Buy
23,519
+28
+0.1% +$393 ﹤0.01% 4174
2023
Q3 		$449K Hold
23,491
– – ﹤0.01% 4083
2023
Q2 		$695K Hold
23,491
– – ﹤0.01% 4016
2023
Q1 		$759K Hold
23,491
– – ﹤0.01% 3993
2022
Q4 		$623K Buy
23,491
+17
+0.1% +$562 ﹤0.01% 4040
2022
Q3 		$911K Hold
23,474
– – ﹤0.01% 4033
2022
Q2 		$704K Sell
23,474
-20,510
-47% -$526K ﹤0.01% 4196
2022
Q1 		$1.27M Hold
43,984
– – ﹤0.01% 4136
2021
Q4 		$1.75M Sell
43,984
-39
-0.1% -$2.09K ﹤0.01% 4093
2021
Q3 		$2.69M Buy
44,023
+70
+0.2% +$5.28K ﹤0.01% 3961
2021
Q2 		$4.01M Buy
43,953
+23,764
+118% +$2.41M ﹤0.01% 3704
2021
Q1 		$2.28M Buy
20,189
+2,255
+13% +$222K ﹤0.01% 3835
2020
Q4 		$1.33M Buy
17,934
+228
+1% +$17.5K ﹤0.01% 3758
2020
Q3 		$1.25M Buy
17,706
+5,971
+51% +$525K ﹤0.01% 3606
2020
Q2 		$1.06M Buy
11,735
+4,064
+53% +$401K ﹤0.01% 3604
2020
Q1 		$586K Buy
7,671
+1,725
+29% +$166K ﹤0.01% 3639
2019
Q4 		$405K Hold
5,946
– – ﹤0.01% 3831
2019
Q3 		$368K Buy
5,946
+2,919
+96% +$165K ﹤0.01% 3869
2019
Q2 		$173K Sell
3,027
-676
-18% -$40.6K ﹤0.01% 3998
2019
Q1 		$254K Buy
3,703
+722
+24% +$70K ﹤0.01% 3880
2018
Q4 		$316K Sell
2,981
-4
-0.1% -$370 ﹤0.01% 3820
2018
Q3 		$92K Buy
2,985
+5
+0.2% +$235 ﹤0.01% 4084
2018
Q2 		$183K Sell
2,980
-4,359
-59% -$322K ﹤0.01% 3987
2018
Q1 		$1.19M Buy
7,339
+1,687
+30% +$413K ﹤0.01% 3610
2017
Q4 		$1.36M Buy
5,652
+10
+0.2% +$2.24K ﹤0.01% 3531
2017
Q3 		$1.35M Sell
5,642
-726
-11% -$145K ﹤0.01% 3511
2017
Q2 		$1.27M Sell
6,368
-867
-12% -$181K ﹤0.01% 3520
2017
Q1 		$1.9M Buy
7,235
+24
+0.3% +$5.47K ﹤0.01% 3397
2016
Q4 		$1.39M Sell
7,211
-135
-2% -$31K ﹤0.01% 3478
2016
Q3 		$2.11M Buy
7,346
+142
+2% +$34.2K ﹤0.01% 3373
2016
Q2 		$1.67M Buy
7,204
+286
+4% +$65.8K ﹤0.01% 3438
2016
Q1 		$1.43M Buy
6,918
+2,107
+44% +$525K ﹤0.01% 3490
2015
Q4 		$1.31M Buy
4,811
+413
+9% +$116K ﹤0.01% 3543
2015
Q3 		$1.15M Buy
+4,398
New +$1.53M ﹤0.01% 3591

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Vanguard Group's VTVT Position: Q4 2025 in Review

Vanguard Group increased its vTv Therapeutics (VTVT) stake by 77% in Q4 2025, buying an estimated $1.01M and bringing the position to 83,400 shares worth $3.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3405.

Vanguard Group first reported a position in VTVT in Q3 2015 and has held it in 42 quarters since. The position peaked at $4.01M in Q2 2021. 27 funds tracked by Wall St. Rank hold VTVT as of Q4 2025.

  • Vanguard Group held 83,400 shares of vTv Therapeutics worth $3.34M as of Q4 2025.
  • Vanguard Group bought 36,410 vTv Therapeutics shares in Q4 2025, an estimated $1.01M.
  • vTv Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3405 holding.
  • Vanguard Group first reported a position in vTv Therapeutics in Q3 2015 and has held it in 42 quarters since.
  • Vanguard Group's vTv Therapeutics position peaked at $4.01M in Q2 2021.
  • 27 funds tracked by Wall St. Rank held vTv Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.